JonesResearch analyst Justin Walsh initiated coverage of Mainz Biomed with a Buy rating and $11 price target. Mainz is a commercial stage in-vitro diagnostics company that is investigating the addition of novel mRNA biomarkers that may be able to detect pre-cancerous polyps, the analyst tells investors in a research note. The firm sees "best-in-class potential" for the company.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MYNZ:
- Mainz Biomed Launches Corporate Health Program in Germany for ColoAlert
- Mainz Biomed Provides Year-End 2022 Corporate Review
- Mainz Biomed announces first patient enrolled in eAArly DETECT study
- Mainz Biomed Enrolls First Patient in eAArly DETECT Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert